Hudson Bay Capital Management
AKRO

Hudson Bay Capital Management’s Akero Therapeutics AKRO Stock Holding History

Hudson Bay Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-338,500
Closed -$16.1M – 1172
2025
Q3 		$16.1M Sell
338,500
-48,023
-12% -$2.33M 0.05% 262
2025
Q2 		$20.6M Buy
386,523
+84,573
+28% +$3.84M 0.07% 209
2025
Q1 		$12.2M Buy
301,950
+126,950
+73% +$5.38M 0.04% 352
2024
Q4 		$4.87M Buy
175,000
+20,000
+13% +$606K 0.02% 509
2024
Q3 		$4.45M Buy
+155,000
New +$4.04M 0.02% 437

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hudson Bay Capital Management's AKRO Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 338,500 shares — an estimated $16.1M sold.

Hudson Bay Capital Management first reported a position in AKRO in Q3 2024 and held it in 5 quarters. The position peaked at $20.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Hudson Bay Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 338,500 Akero Therapeutics shares in Q4 2025, an estimated $16.1M.
  • Hudson Bay Capital Management first reported a position in Akero Therapeutics in Q3 2024 and held it in 5 quarters.
  • Hudson Bay Capital Management's Akero Therapeutics position peaked at $20.6M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.